U.S. Non-oncology Biopharmaceuticals Market, by Product Type (Biologics and Biosimilars), by Drug Class (Monoclonal Antibody, Enzyme Replacement Therapy, Erythropoietin, Interferon, Colony-stimulating Factor, Botulinum Toxin, Fusion Protein, Vaccines, Human Recombinant Insulin, Blood Factors, Human Growth Hormone, and Others), and by Disease Indication (Diabetes, Rheumatoid Arthritis, Psoriatic Arthritis, Multiple Sclerosis, Hemophilia, Anemia, Age-related Macular Degeneration, Hepatitis B, Cystic Fibrosis, Osteoporosis, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, and Others (Cardiac Diseases and Others)) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Apr 2019 |
  • Pages : 224 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

U.S. Non-oncology Biopharmaceuticals Market- Insights

Biologics can be defined as molecules derived from living cells such as microorganisms, plants or animal cells and used in the treatment, diagnosis or prevention of diseases. Most of the biologic molecules are very large, complex molecules or mixture of molecules.

Biopharmaceuticals are part of a wider category of therapeutic agents called biologics. Biopharmaceuticals are the substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs that are used in the treatment of various diseases rather than cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Increasing launches, approvals, and robust pipeline of novel biopharmaceuticals for non-oncology indications

Frequent approvals, launches, and robust pipeline of novel non-oncology biopharmaceuticals for various indications in the U.S. market is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth.

For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.

In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.

In July 2018, Amgen Inc. and UCB Inc. resubmitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

The U.S. non-oncology biopharmaceuticals market size was valued at US$ 116.0 Bn in 2018 and is expected to witness a CAGR of 10.2% during the forecast period (2018 – 2026).

Figure 1. U.S. Non-oncology Biopharmaceuticals Market Share (%), By Product Type, 2018-2026

U.S. Non-oncology Biopharmaceuticals  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Increasing mergers and collaborations among key players for development of novel non-oncology biopharmaceuticals is expected to support the market growth

Key players in the market are involved in strategic mergers and collaborations for the development of new biopharmaceutical products and to market them in the U.S. Such strategic mergers and collaborations between key players is expected to support the development of novel products, which in turn is expected to fuel the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in 2017, Sanofi S.A. and its vaccines business unit Sanofi Pasteur collaborated with MedImmune, the global biologics research and development arm of AstraZeneca Plc., for the development and commercialization of a monoclonal antibody, namely MEDI8897, for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.

High price of branded biologic products is expected to be a major factor negatively affecting its adoption

According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.

Table 1. Revenue of Top Non-oncology Biopharmaceutical Brands in the U.S.

U.S. Non-oncology Biopharmaceuticals  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Market Opportunity

In the recent past, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future.

Loss of patent in the U.S. market offers lucrative opportunity to other players for development of its biosimilars. Hence, key players in the market are focused on launch and development of biosimilars of biologic products in the market at affordable price.

For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc. As per the company, RENFLEXIS is introduced in the U.S. at a list price (wholesaler acquisition cost) of US$ 753.39, representing a 35% discount to the current list price of Remicade, which is its reference product.

Market Challenges

High R&D Investments: Developing an IV/injectable biopharmaceutical requires sophisticated infrastructure, skilled scientists, and significant resource investment. Development of a biopharmaceutical product requires extensive clinical research and multiple phases of trials, which is a lengthy and expensive process. These factors are significant barriers for the new players to enter the market.

Sales and Marketing: The U.S. non-oncology biopharmaceuticals market has established market players with strong sales and marketing team. Presence of such strong players in the country creates a big challenge for new players to enter the market and to sustain against such big players.

Physician Acceptance: Physician acceptance of substitutes for well-established products may be a challenge, particularly among indications for which numerous products are available and substitutes do not exhibit high/ better safety profile and/or lower cost.

Key players operating in the U.S. non-oncology biopharmaceuticals market include Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.

Biopharmaceuticals are complex, high molecular weight proteins and peptides that are produced or synthesized from living biological source. Biopharmaceuticals are further divided into biologics and biosimilars.

Biologics can be defined as molecules derived from the living cells such as microorganisms, or plant or animal cells and used in the treatment, diagnosis, or prevention of diseases. Most of the biologic molecules are very large, complex molecules, or mixture of molecules. The U.S. Food and Drug Administration (FDA) defines biosimilar as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

Non-oncology biopharmaceuticals are drugs which are indicated for treatment of a number of diseases except cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Market Dynamics

Frequent launch, approval, and presence of robust pipeline of novel biopharmaceutical products indicated for treatment of number of non-oncology indication is expected to drive the U.S. non-oncology biopharmaceuticals market growth over the forecast period. For instance, in November 2018, Swedish Orphan Biovitrum AB and Novimmune SA received the U.S. Food and Drug Administration (FDA) approval for Gamifant (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (new born and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.

In March 2018, Theratechnologies Inc. and its partner TaiMed Biologics Inc. received the U.S. Food and Drug Administration (FDA) approval for its Trogarzo (ibalizumab-uiyk) Injection. In combination with other ARTs, Trogarzo is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection, who are failing their current antiretroviral regimen.

Key players in the market are adopting inorganic growth strategies such as mergers and partnerships for the development of novel products or to expand their product portfolio by acquisition. Such frequent activities by key players is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in 2016, Teva Pharmaceutical Industries Ltd. and Celltrion Inc. entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada.

In 2016, Shire plc. and Baxalta Incorporated entered into an agreement, under which Shire will combine with Baxalta. Baxalta has a well-established hematology portfolio based on its heritage and legacy of leadership in hemophilia. With this merger, the established company (Shire plc.) will strengthen its position in the market.

Furthermore, high prevalence of various chronic disorders such as diabetes, asthma, cardiovascular diseases, and arthritis in the U.S. is expected to increase demand for biopharmaceutical products and in turn support the non-oncology biopharmaceuticals market growth. For instance, according to the data published by Centers for Disease Control and Prevention (CDC), in 2017, over 100 million U.S. adults were suffering from diabetes or pre-diabetes.

Key features of the study:

  • This report provides in-depth analysis of U.S. non-oncology biopharmaceuticals market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the U.S. Non-oncology biopharmaceuticals market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol - Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The U.S. non-oncology biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the U.S. non-oncology biopharmaceuticals market

Detailed Segmentation:

  • U.S. Non-oncology Biopharmaceuticals Market, By Product Type :
    • Biologics
    • Biosimilars
  • U.S. Non-oncology Biopharmaceuticals Market, By Drug Class:
    • Monoclonal Antibody
    • Enzyme Replacement Therapy
    • Erythropoietin
    • Interferon
    • Colony-stimulating Factor
    • Botulinum Toxin
    • Fusion Protein
    • Vaccines
    • Human Recombinant Insulin
    • Blood Factors
    • Human Growth Hormone
    • Others
  • U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication:
    • Diabetes
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Multiple Sclerosis
    • Hemophilia
    • Anemia
    • Age-related Macular Degeneration
    • Hepatitis B
    • Cystic Fibrosis
    • Osteoporosis
    • Crohn’s Disease
    • Ulcerative Colitis
    • Psoriasis
    • Ankylosing Spondylitis
    • Others (Cardiac diseases and others)
  • Company Profiles
    • Sanofi S.A.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Bristol - Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • Novo Nordisk A/S
    • GlaxoSmithKline plc.
    • UCB Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Ltd
    • AstraZeneca Plc
    • Mylan N.V.
    • LEO Pharma A/S
    • Boehringer Ingelheim GmbH
    • Alexion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Elusys Therapeutics, Inc.
    • Swedish Orphan Biovitrum AB
    • Samsung Bioepis NL B.V.
    • Biogen Inc.
    • Theratechnologies Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Disease Indication
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Recent Product Approval/Launch
    • Merger-Acquisition Scenario
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pest Analysis
    • Market Challenges
    • Top 10 Non-oncology Biologics Brand Share
    • Major Biopharmaceuticals Administration Method
    • Analysis Of Mode Of Administration
    • Epidemiology
    • Pest Analysis
    • Porter’s Five Forces Analysis
  4. U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2016 – 2026 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Biologics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Biosimilars
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
  5. U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2016 – 2026 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Blood Factors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Botulinum Toxin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Colony-stimulating Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Enzyme Replacement Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Erythropoietin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Fusion Protein
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Human Growth Hormone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Interferon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Monoclonal Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Recombinant Human Insulin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
  6. U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2016 – 2026 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Age-related Macular Degeneration
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Anemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Ankylosing Spondylitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Crohn’s Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Cystic Fibrosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Hemophilia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Hepatitis B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Multiple Sclerosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Osteoporosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Psoriasis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Psoriatic Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Rheumatoid Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Ulcerative Colitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol - Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • UCB Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Takeda Pharmaceutical Company Ltd
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • LEO Pharma A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Alexion Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Elusys Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Swedish Orphan Biovitrum AB
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Samsung Bioepis NL B.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biogen Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Theratechnologies Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 38 figures on “U.S. Non-oncology Biopharmaceuticals Market – U.S. forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.